Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy...
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
About this item
Full title
Author / Creator
Musacchio, Lucia , Salutari, Vanda , Pignata, Sandro , Braicu, Elena , Cibula, David , Colombo, Nicoletta , Frenel, Jean Sebastien , Zagouri, Flora , Carbone, Vittoria , Ghizzoni, Viola , Giolitto, Serena , Giudice, Elena , Perri, Maria Teresa , Ricci, Caterina , Scambia, Giovanni and Lorusso, Domenica
Publisher
United States: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
United States: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundPlatinum-resistant ovarian cancer patients have a poor prognosis and few treatment options are available. Preclinical and clinical data demonstrated that the combination of poly-ADP ribose polymerase inhibitors with immune checkpoint inhibitors could have a synergistic antitumor activity in this setting of patients.Primary ObjectiveThe pr...
Alternative Titles
Full title
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2579380945
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2579380945
Other Identifiers
ISSN
1048-891X
E-ISSN
1525-1438
DOI
10.1136/ijgc-2021-002593
